Loading...
| A02427 | Pages: 193 | Mar 2020 | 8674 Views | | |
| Author(s) : Sagar Mukhekar , Onkar Sumant | Tables: 73 | Charts: 51 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Antimalarial Drugs Market
Request Now !The global antimalarial drugs market accounted for $711,360 thousand in 2018 and is expected to reach $1,019,396 thousand by 2026, registering a CAGR of 4.6% from 2019 to 2026.
Malaria is an infectious disease, which spreads through a bite of infected female Anopheles mosquito, transferring parasites into the human body. Furthermore, these parasites lodge into liver cells where they multiply and grow. They then move to red blood cells to reach a stage called merozoites. These merozoites grow inside the red cells and destroy them which further cause symptoms such as fever, tiredness, vomiting, and headache. In addition, the drugs that are used to treat and prevent malarial infection are called as antimalarial. There are different type of drugs, such as quinine, chloroquine, proguanil, mefloquine, pyrimethamine, and others, available in the market for the treatment of malarial infection.
Get more information on this report : Request Sample Pages
The major factor that drives the growth of the antimalarial drugs market include rise in prevalence of malaria in developing countries. Furthermore, rise in awareness initiatives by governments and surge in research for new antimalarial drugs are some of the factors that boost the growth of the market. However, lack of awareness about healthcare in developing countries is a major factor that restrains the growth of the antimalarial drugs market. Conversely, growth opportunities exhibited by emerging economies are expected to offer lucrative opportunities for the market expansion during the forecast period.
Antimalarial Drugs Market Segmentation
The antimalarial drugs market size is studied on the basis of drug class, distribution channel, and region to provide a detailed assessment of the market. On the basis of drug class, it is segmented into quinine, chloroquine, proguanil, mefloquine, pyrimethamine, and others. By distribution channel, it is divided into hospital pharmacy, retail pharmacy, and e-commerce & other distribution channel. Region wise, it is analyzed across North America (the U.S. and Canada), Europe (Germany, the UK, and rest of Europe), Asia-Pacific (China, India, and rest of Asia-Pacific), and LAMEA (Africa and rest of LAMEA).
Segment Review
According to drug class, the others segment occupied the major share of the antimalarial drugs market. Furthermore, the segment is also expected to exhibit the fastest growth rate during the forecast period, owing to factor that malaria parasites have successfully developed resistance against most of the drugs already available in the market.
Get more information on this report : Request Sample Pages
By distribution channel, the hospital pharmacy segment acquired the major share due to rise in number of hospitals worldwide. Furthermore, antimalarial drugs are prescription-based medications, which are mostly prescribed by the specialized healthcare professionals available in hospitals; thereby, propelling the growth of this segment. Conversely, the e-commerce segment is expected to exhibit the fastest growth rate during the forecast period, owing to surge in the usage of internet across the globe.
Get more information on this report : Request Sample Pages
By region, LAMEA accounted for the major antimalarial drugs market share in 2018 and is expected to continue this trend, owing to rapid surge in prevalence of malaria in the region. Moreover, the widespread of the malaria vector, Anopheles gambiae, in the region, which is difficult to control is another major factor that leads to surge in cases of malaria. Furthermore, most of the malarial infections in this region are caused by the most lethal type of malarial parasite called Plasmodium falciparum. Therefore, there is a need for early diagnosis of malarial infection in this region, which further boosts the growth of the market. In addition, malaria infection is endemic to some parts of Africa, which fuels the growth of the market in the region. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period due to increase in awareness regarding the use of antimalarial drugs for early diagnosis of the infection for better treatment. The constantly evolving life science industry drives the growth of the market in developing economies such as India, China, and Malaysia. As the constant development leads to surge in awareness related to the use of antimalarial drugs.
Get more information on this report : Request Sample Pages
The global antimalarial drugs market is highly competitive and the prominent players in the market have adopted various strategies to garner maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Alvizia Healthcare Pvt. Ltd., Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Ipca Laboratories Ltd., Merck & Co., Inc, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories), and Zydus Cadila.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.2.1. List of key players profiled in the report
1.3. Research methodology
1.3.1. Primary research
1.3.2. Secondary research
1.3.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Top player positioning
3.2.1. Top investment pockets
3.3. Key forces shaping antimalarial drugs industry/market
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of malaria
3.4.1.2. Surge in healthcare expenditure worldwide
3.4.1.3. Presence of large number of pipeline products
3.4.2. Restraint
3.4.2.1. Poor demand in underdeveloped countries
3.4.3. Opportunity
3.4.3.1. High growth potential in developing economies
3.4.4. Impact Analyses
CHAPTER 4: ANTIMALARIAL DRUGS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Quinine
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Chloroquine
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Proguanil
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Mefloquine
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Pyrimethamine
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
4.7. Others
4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country
CHAPTER 5: ANTIMALARIAL DRUGS MARKET, BY DISTRIBUTION CHANNEL
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospital pharmacy
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Retail Pharmacy
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. E-commerce & other distribution channels
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
CHAPTER 6: ANTIMALARIAL DRUGS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. Market analysis, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. market size and forecast, by drug class
6.2.2.1.2. U.S. market size and forecast, by distribution channel
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by drug class
6.2.2.2.2. Canada market size and forecast, by distribution channel
6.2.3. North America market size and forecast, by drug class
6.2.4. North America market size and forecast, by distribution channel
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Market analysis, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by drug class
6.3.2.1.2. Germany market size and forecast, by distribution channel
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by drug class
6.3.2.3.2. UK market size and forecast, by distribution channel
6.3.2.3. Rest of Europe
6.3.2.3.1. Rest of Europe market size and forecast, by drug class
6.3.2.3.2. Rest of Europe market size and forecast, by distribution channel
6.3.3. Europe market size and forecast, by drug class
6.3.4. Europe market size and forecast, by distribution channel
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Market analysis, by country
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by drug class
6.4.2.2.2. China market size and forecast, by distribution channel
6.4.2.3. India
6.4.2.3.1. India market size and forecast, by drug class
6.4.2.3.2. India market size and forecast, by distribution channel
6.4.2.4. Rest of Asia-Pacific
6.4.2.4.1. Rest of Asia-Pacific market size and forecast, by drug class
6.4.2.4.2. Rest of Asia-Pacific market size and forecast, by distribution channel
6.4.3. Asia-Pacific market size and forecast, by drug class
6.4.4. Asia-Pacific market size and forecast, by distribution channel
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. Market analysis, by country
6.5.2.1. Africa
6.5.2.1.1. Africa market size and forecast, by drug class
6.5.2.1.2. Africa market size and forecast, by distribution channel
6.5.2.2. Rest of LAMEA
6.5.2.2.1. Rest of LAMEA market size and forecast, by drug class
6.5.2.2.2. Rest of LAMEA market size and forecast, by distribution channel
6.5.3. LAMEA market size and forecast, by drug class
6.5.4. LAMEA market size and forecast, by distribution channel
CHAPTER 7: COMPANY PROFILES
7.1. Alvizia Healthcare Pvt. Ltd.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.2. Bayer AG.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.1. Key strategic moves and developments
7.3. F. Hoffmann-La Roche Ltd.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. GlaxoSmithKline Plc
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. Ipca Laboratories Ltd.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. Merck & Co., Inc
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.7. NOVARTIS AG
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. Pfizer Inc.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories)
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.10. Zydus Cadila
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL ANTIMALARIAL DRUGS MARKET, BY DRUG CLASS, 2018-2026 ($THOUSAND)
TABLE 02. QUININE ANTIMALARIAL DRUGS MARKET, BY REGION, 2018–2026 ($THOUSAND)
TABLE 03. CHLOROQUINE ANTIMALARIAL DRUGS MARKET, BY REGION, 2018–2026 ($THOUSAND)
TABLE 04. PROGUANIL ANTIMALARIAL DRUGS MARKET, BY REGION, 2018–2026 ($THOUSAND)
TABLE 05. MEFLOQUINE ANTIMALARIAL DRUGS MARKET, BY REGION, 2018–2026 ($THOUSAND)
TABLE 06. PYRIMETHAMINE ANTIMALARIAL DRUGS MARKET, BY REGION, 2018–2026 ($THOUSAND)
TABLE 07. OTHERS ANTIMALARIAL DRUGS MARKET, BY REGION, 2018–2026 ($THOUSAND)
TABLE 08. GLOBAL ANTIMALARIAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($THOUSAND)
TABLE 09. HOSPITAL PHARMACY ANTIMALARIAL DRUGS MARKET, BY REGION, 2018–2026 ($THOUSAND)
TABLE 10. RETAIL PHARMACY ANTIMALARIAL DRUGS MARKET, BY REGION, 2018–2026 ($THOUSAND)
TABLE 11. E-COMMERCE & OTHER DISTRIBUTION CHANNELS ANTIMALARIAL DRUGS MARKET, BY REGION, 2018–2026 ($THOUSAND)
TABLE 12. ANTIMALARIAL DRUGS MARKET, BY REGION, 2018-2026 ($THOUSAND)
TABLE 13. NORTH AMERICA ANTIMALARIAL DRUGS MARKET REVENUE, BY COUNTRY, 2019–2026 ($THOUSAND)
TABLE 14. U.S. ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($THOUSAND)
TABLE 15. U.S. ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($THOUSAND)
TABLE 16. CANADA ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($THOUSAND)
TABLE 17. CANADA ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($THOUSAND)
TABLE 18. NORTH AMERICA ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($THOUSAND)
TABLE 19. NORTH AMERICA ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($THOUSAND)
TABLE 20. EUROPE ANTIMALARIAL DRUGS MARKET REVENUE, BY COUNTRY, 2019–2026 ($THOUSAND)
TABLE 21. GERMANY ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($THOUSAND)
TABLE 22. GERMANY ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($THOUSAND)
TABLE 23. UK ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($THOUSAND)
TABLE 24. UK ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($THOUSAND)
TABLE 25. REST OF EUROPE ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($THOUSAND)
TABLE 26. REST OF EUROPE ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($THOUSAND)
TABLE 27. EUROPE ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($THOUSAND)
TABLE 28. EUROPE ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026($THOUSAND)
TABLE 29. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET REVENUE, BY COUNTRY, 2019–2026 ($THOUSAND)
TABLE 30. CHINA ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($THOUSAND)
TABLE 31. CHINA ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($THOUSAND)
TABLE 32. INDIA ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($THOUSAND)
TABLE 33. INDIA ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($THOUSAND)
TABLE 34. REST OF ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($THOUSAND)
TABLE 35. REST OF ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($THOUSAND)
TABLE 36. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($THOUSAND)
TABLE 37. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026($THOUSAND)
TABLE 38. LAMEA ANTIMALARIAL DRUGS MARKET REVENUE, BY COUNTRY, 2019–2026 ($THOUSAND)
TABLE 39. AFRICA ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($THOUSAND)
TABLE 40. AFRICA ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($THOUSAND)
TABLE 41. REST OF LAMEA ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($THOUSAND)
TABLE 42. REST OF LAMEA ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($THOUSAND)
TABLE 43. LAMEA ANTIMALARIAL DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($THOUSAND)
TABLE 44. LAMEA ANTIMALARIAL DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026($THOUSAND)
TABLE 45. ALVIZIA: COMPANY SNAPSHOT
TABLE 46. ALVIZIA HEALTHCARE PVT. LTD.: PRODUCT SEGMENTS
TABLE 47. ALVIZIA: PRODUCT PORTFOLIO
TABLE 48. BAYER: COMPANY SNAPSHOT
TABLE 49. BAYER: OPERATING SEGMENTS
TABLE 50. BAYER: PRODUCT PORTFOLIO
TABLE 51. ROCHE: COMPANY SNAPSHOT
TABLE 52. ROCHE: OPERATING SEGMENTS
TABLE 53. ROCHE: PRODUCT PORTFOLIO:
TABLE 54. GSK: COMPANY SNAPSHOT
TABLE 55. GSK: OPERATING SEGMENTS
TABLE 56. GSK: PRODUCT PORTFOLIO
TABLE 57. IPCA: COMPANY SNAPSHOT
TABLE 58. IPCA: OPERATING SEGMENTS
TABLE 59. IPCA: PRODUCT PORTFOLIO
TABLE 60. MERCK: COMPANY SNAPSHOT
TABLE 61. MERCK: OPERATING SEGMENTS
TABLE 62. MERCK: PRODUCT PORTFOLIO
TABLE 63. NOVARTIS: COMPANY SNAPSHOT
TABLE 64. NOVARTIS: OPERATING SEGMENTS
TABLE 65. NOVARTIS: PRODUCT PORTFOLIO
TABLE 66. PFIZER: COMPANY SNAPSHOT
TABLE 67. PFIZER: OPERATING SEGMENTS
TABLE 68. PFIZER: PRODUCT PORTFOLIO
TABLE 69. SUN PHARMA.: COMPANY SNAPSHOT
TABLE 70. SUN PHARMA: OPERATING SEGMENTS
TABLE 71. SUN PHARMA: PRODUCT PORTFOLIO
TABLE 72. ZYDUS: COMPANY SNAPSHOT
TABLE 73. ZYDUS: OPERATING SEGMENTS
TABLE 74. ZYDUS: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. GLOBAL ANTIMALARIAL DRUGS MARKET SEGMENTATION
FIGURE 02. TOP PLAYER POSITIONING, 2018
FIGURE 03. TOP INVESTMENT POCKETS
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. HIGH INTENSITY OF RIVALRY
FIGURE 08. LOW THREAT OF NEW ENTRANT
FIGURE 09. IMPACT ANALYSES, ANTIMALARIAL DRUGS MARKET
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF QUININE ANTIMALARIAL DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CHLOROQUINE ANTIMALARIAL DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PROGUANIL ANTIMALARIAL DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MEFLOQUINE ANTIMALARIAL DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PYRIMETHAMINE ANTIMALARIAL DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF OTHERS ANTIMALARIAL DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACY ANTIMALARIAL DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACY ANTIMALARIAL DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF E-COMMERCE & OTHER DISTRIBUTION CHANNELS ANTIMALARIAL DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 19. U.S. ANTIMALARIAL DRUGS MARKET, 2018-2026 ($THOUSAND)
FIGURE 20. CANADA ANTIMALARIAL DRUGS MARKET, 2018-2026 ($THOUSAND)
FIGURE 21. GERMANY ANTIMALARIAL DRUGS MARKET, 2018-2026 ($THOUSAND)
FIGURE 22. UK ANTIMALARIAL DRUGS MARKET, 2018-2026 ($THOUSAND)
FIGURE 23. REST OF EUROPE ANTIMALARIAL DRUGS MARKET, 2018-2026 ($THOUSAND)
FIGURE 24. CHINA ANTIMALARIAL DRUGS MARKET, 2018-2026 ($THOUSAND)
FIGURE 25. INDIA ANTIMALARIAL DRUGS MARKET, 2018-2026 ($THOUSAND)
FIGURE 26. REST OF ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET, 2018-2026 ($THOUSAND)
FIGURE 27. AFRICA ANTIMALARIAL DRUGS MARKET, 2018-2026 ($THOUSAND)
FIGURE 28. REST OF LAMEA ANTIMALARIAL DRUGS MARKET, 2018-2026 ($THOUSAND)
FIGURE 29. BAYER: NET SALES, 2016–2018 ($MILLION)
FIGURE 30. BAYER: REVENUE SHARE BY SEGMENTS, 2018(%)
FIGURE 31. BAYER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 32. ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 33. ROCHE: REVENUE SHARE BY SEGMENTS, 2018(%)
FIGURE 34. ROCHE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 35. GSK: NET SALES, 2017–2018 ($MILLION)
FIGURE 36. GSK REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 37. GSK: REVENUE SHARE BY REGIONS, 2018 (%)
FIGURE 38. IPCA LABORATORIES LTD.: NET SALES, 2016–2018 ($MILLION)
FIGURE 39. MERCK: NET SALES, 2016–2018 ($MILLION)
FIGURE 40. MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 41. MERCK: REVENUE SHARE BY REGION, 2018(%)
FIGURE 42. NET SALES, 2016–2018 ($MILLION)
FIGURE 43. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 44. NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 45. PFIZER: NET SALES, 2016–2018 ($MILLION)
FIGURE 46. PFIZER: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 47. PFIZER: REVENUE SHARE BY REGION, 2018(%)
FIGURE 48. SUN PHARMA: NET SALES, 2018–2019 ($MILLION)
FIGURE 49. SUN PHARMA: REVENUE SHARE BY REGION, 2018(%)
FIGURE 50. ZYDUS: NET SALES, 2017–2019 ($MILLION)
FIGURE 51. ZYDUS: REVENUE SHARE BY REGION, 2019(%)
Antimalarial drugs are defined as medicines that are used in the treatment and prevention of malarial infection caused by the bite of female Anopheles mosquito. Furthermore, malaria is a deadly disease if left untreated as the parasites destroy the blood cells of the host. This leads to critical symptoms such as impaired consciousness; multiple convulsions; abnormal bleeding and signs of anemia, fever, and chills; and others. Therefore, there are different types of antimalarial drugs, such as quinine, chloroquine, proguanil, mefloquine, pyrimethamine, and others, which are used to treat the infection.
The utilization of antimalarial drugs has witnessed a significant growth, owing to surge in prevalence of malaria across the globe. Furthermore, other factors that contribute to the growth of the market include surge in healthcare expenditure, rise in research relate to new antimalarial drugs, and increase in initiatives by governments.
A. The total market value of antimalarial drugs market is $711,360 thousand in 2018.
A. The forcast period for antimalarial drugs market is 2019 to 2026
A. The market value of antimalarial drugs market in 2019 is $744,083 thousand
A. The base year is 2018 in antimalarial drugs market
A. Top companies such as, GlaxoSmithKline Plc., Zydus Cadila, Ipca Laboratories Ltd., Bayer AG., and Novartis AG held a high market position in 2018. These key players held a high market postion owing to the strong geographical foothold in different regions.
A. Others segment is the most influencing segment growing in the antimalarial drugs market owing to surge in resistance to most of the antimalarial drugs available previously is another major that leads to surge in demand for new antimalarial drugs in the market
A. The key trend in the antimalarial drugs market is the rise in prevalence of malaria across the globe which drives the growth of the market. This leads to surge in the demand for antimalarial drugs which boots the growth of the market.
A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 5.6%. This is due to surge in the surge in awareness related to use of antimalarial drugs for treatment of malaria .
A. Antimalarial drugs are defined as medications which are aimed at prevention and treatment of malaria. Furthermore, antimalarial drugs have different mechanism of action on the malaria parasites. Some of the common antimalrial drug types include Quinine, Chloroquine and others.
A. Antimalarial drugs are used to treat and prevent malaria which is a fatal parasitic infection caused by Anopheles mosquito. Some of the common symptoms of malaria include chills, profuse sweating, nausea, headache and others.
Enterprise
License/PDF
Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
